Albain KS, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-88 H).Proc Am Soc Clin Oncol 2002; 21:37a (abstract 143).

ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the AT AC randomised trial. Lancet 2002; 359:2131.

Byers T: Nutritional risk factors for breast cancer. Cancer 74:288, 1994

Citron ML, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia group trial 9741. J Clin Oncol 2003; 21:1431.

Dickson RB, Lippman ME: Growth factors in breast cancer. Endoer Rev 16:559, 1995

Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1:71, 1992

Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451.

Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352:930.

Fisher et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674, 1985

Fisher B, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993.

Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17. Intraductal carcinoma. Cancer 1999; 86:429.

Friedman LS et al: The search for BRCA1. Cancer Res 54:6374, 1994

Gebauer G, et al. Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat 2002; 75:167.

Goldhirsch A, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21:3357.

Goss PE, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 349:1793.

Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second- line hormonal treatment of advanced breast cancer. Ann Oncol 1999; 10:377.

Harris J et al: Breast cancer: Recent trends and progress and future prospects. Parts I, II, III. N Engl J Med 327:319, 390, 473, 1992

Harris J et al. (eds): Diseases of the Breast. Philadelphia, Lippincott-Raven, 1995

Harris J R, Hellman S. Natural history of breast cancer. In: Harris J R, Lip- pman ME, Morrow M, Hellman S (eds). Diseases of the breast. New York-Philadelphia: Lippincott, 1996.

Henderson 1, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 2003; 21:976.

Hillner BE, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042.

Hortobagyi GN, Singletary SE, Strom EA. Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, ed. Diseases of the breast. Philadelphia, Pa: Lippincott Williams & Wilkins, 2000.

Jemel A, Murray T, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5.

Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pTINOMO breast carcinoma. Cancer 1999; 85:2183.

Julien JP, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355:528.

Kattlove H, Winn RJ. Ongoing care of patients after primary treatment for their cancer. CA Cancer J Clin 2003; 53:172.

Morrow M, et al. Standard for the management of ductal carcinoma in situ of the breast (DC1S). CA Cancer J Clin 2002; 52:256.

Morrow M, et al. Standard for breast conservation therapy in the management of invasive breast cancer. CA Cancer J Clin 2002; 52:277.

Recht A, et al. Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin OncollW 1; 19:1539.

Santen RJ et al: Endocrine treatment of breast cancer in women. Endocr Rev 11:221, 1990

Shapiro S: Screening: Assessment of current studies. Cancer 74(Suppl):231, 1994

Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against H ER2 for metastatic breast cancer that overexpresses H ER2. N Engl J Med 2001; 344:783.

Smith RA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003; 54:141.

Weiss RB, et al. Natural history of more than 20 years of node- positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol 2003; 21:1825.

Wooster R, Weber BL. Genomic medicine: breast and ovarian cancer. N Engl J Med 2003; 348:2339.


  • ()